Literatur
- 1
Panzram G, Zabel-Langhennig R.
Prognosis of diabetes mellitus in a geographically defined population.
Diabetologia.
1981;
20
587-591
- 2
Herholz H.
Diabeteskosten: Teuer sind Komplikationen.
Diabetes, Stoffwechsel und Herz.
2006;
S 1
7-11
- 3
Stratton I M, Adler A I, Neil H A et al.
Association of glycaemia with macrovascular and microvascular complications of type 2
diabetes (UKPDS 35): prospective observational study.
BMJ.
2000;
321
405-412
- 4
Holman R R, Paul S K, Bethel M A et al.
10-year follow-up of intensive glucose control in type 2 diabetes.
N Engl J Med.
2008;
359
1577-1589
- 5
The Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions
and Complications Research Group .
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial
of intensive therapy.
N Engl J Med.
2000;
342
381-389
- 6
Juutilainen A, Lehto S, Ronnemaa T et al.
Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality
in middle-aged subjects.
Diabetes Care.
2008;
31
714-719
- 7
Gerstein H C, Miller M E, Byington R P Action to Control Cardiovascular Risk in Diabetes
Study Group et al.
Effects of intensive glucose lowering in type 2 diabetes.
N Engl J Med.
2008;
358
2545-2559
- 8
Patel A, MacMahon S, Chalmers J ADVANCE Collaborative Group et al.
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
N Engl J Med.
2008;
358
2560-2572
- 9 VADT-Präsentation zur ADA 2008.
- 10 Chalmers J. Präsentation zur EASD 2008.
- 11
Dluhy R G, McMahon G T.
Intensive glycemic control in the ACCORD and ADVANCE trials.
N Engl J Med.
2008;
358
2630-2633
- 12
Cefalu W T.
Glycemic targets and cardiovascular disease.
N Engl J Med.
2008;
358
2633-2635
- 13
Schulze J.
„ACCORD” und „ADVANCE” – Wie gefährlich ist die aggressive HbA1c Absenkung bei Typ-2-Diabetes
mellitus?.
Z Evid Fortbild Qual Gesundhwesen.
2008;
102
402-403
- 14
Rao A D, Kuhadiya N, Reynolds K et al.
Is the combination of sulfonylureas and metformin associated with an increased risk
of cardiovascular disease or all-cause mortality?: a meta-analysis of observational
studies.
Diabetes Care.
2008;
31
1672-1678
- 15
Hanefeld M, Fischer S, Julius U et al.
Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes
Intervention Study, 11-year follow-up.
Diabetologia.
1996;
39
1577-1583
- 16
Gaede P, Lund-Andersen H, Parving H H et al.
Effect of a multifactorial intervention on mortality in type 2 diabetes.
N Engl J Med.
2008;
358
580-591
- 17
Hanefeld M, Bornstein S, Pistrosch F.
Shifting the disease management paradigm from glucose – Contra argument.
Diabetes Care.
2009;
, in press
- 18
Stamler J, Vaccaro O, Neaton J D et al.
Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened
in the Multiple Risk Factor Intervention Trial.
Diabetes Care.
1993;
16
434-444
- 19
Hanefeld M.
Normnahe postprandiale Hyperglykämie – eine essenzielle Komponente guter Diabeteskontrolle
und Prävention kardiovaskulärer Erkrankungen.
Diabetologie.
2007;
2
62-69
- 20
Dormandy J A, Charbonnel B, Eckland D J PROactive investigators et al.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the
PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):
a randomised controlled trial.
Lancet.
2005;
366
1279-1289
- 21
UK Prospective Diabetes Study (UKPDS) Group .
Effect of intensive blood-glucose control with metformin on complications in overweight
patients with type 2 diabetes (UKPDS 34).
Lancet.
1998;
352
854-865
- 22
Hanefeld M, Cagatay M, Petrowitsch T et al.
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis
of seven long-term studies.
Eur Heart J.
2004;
25
10-16
Prof. Dr. med. Markolf Hanefeld
GWT-TUD GmbH · Zentrum für Klinische Studien · Forschungsbereich Stoffwechsel und
Endokrinologie
Fiedlerstr. 34
01307 Dresden
Phone: 03 51 / 4 40 05 93
Fax: 03 51 / 4 40 05 81
Email: hanefeld@gwtonline-zks.de
